Literature DB >> 28450705

The ETS family of oncogenic transcription factors in solid tumours.

Gina M Sizemore1,2, Jason R Pitarresi1,2, Subhasree Balakrishnan1,2, Michael C Ostrowski1,2.   

Abstract

Findings over the past decade have identified aberrant activation of the ETS transcription factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene rearrangement and amplification, feed-forward growth factor signalling loops, formation of gain-of-function co-regulatory complexes and novel cis-acting mutations in ETS target gene promoters can result in increased ETS activity. In turn, pro-oncogenic ETS signalling enhances tumorigenesis through a broad mechanistic toolbox that includes lineage specification and self-renewal, DNA damage and genome instability, epigenetics and metabolism. This Review discusses these different mechanisms of ETS activation and subsequent oncogenic implications, as well as the clinical utility of ETS factors.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28450705     DOI: 10.1038/nrc.2017.20

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  195 in total

Review 1.  A review of post-translational modifications and subcellular localization of Ets transcription factors: possible connection with cancer and involvement in the hypoxic response.

Authors:  Céline Charlot; Hélène Dubois-Pot; Tsvetan Serchov; Yves Tourrette; Bohdan Wasylyk
Journal:  Methods Mol Biol       Date:  2010

2.  Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis.

Authors:  Guo Wei; Ruchika Srinivasan; Carmen Z Cantemir-Stone; Sudarshana M Sharma; Ramasamy Santhanam; Michael Weinstein; Natarajan Muthusamy; Albert K Man; Robert G Oshima; Gustavo Leone; Michael C Ostrowski
Journal:  Blood       Date:  2009-05-01       Impact factor: 22.113

3.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

4.  [Chromosomal translocation (11; 22) in cell lines of Ewing's sarcoma].

Authors:  C Turc-Carel; I Philip; M P Berger; T Philip; G Lenoir
Journal:  C R Seances Acad Sci III       Date:  1983

5.  ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.

Authors:  Nicole Longoni; Manuela Sarti; Domenico Albino; Gianluca Civenni; Anastasia Malek; Erica Ortelli; Sandra Pinton; Maurizia Mello-Grand; Paola Ostano; Gioacchino D'Ambrosio; Fausto Sessa; Ramon Garcia-Escudero; George N Thalmann; Giovanna Chiorino; Carlo V Catapano; Giuseppina M Carbone
Journal:  Cancer Res       Date:  2013-05-16       Impact factor: 12.701

6.  A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein.

Authors:  Marius S Pop; Nicolas Stransky; Colin W Garvie; Jean-Philippe Theurillat; Emily C Hartman; Timothy A Lewis; Cheng Zhong; Elizabeth K Culyba; Fallon Lin; Douglas S Daniels; Raymond Pagliarini; Lucienne Ronco; Angela N Koehler; Levi A Garraway
Journal:  Mol Cancer Ther       Date:  2014-04-15       Impact factor: 6.261

Review 7.  ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review).

Authors:  David Adler; Nicolas Wernert
Journal:  Int J Oncol       Date:  2012-02-21       Impact factor: 5.650

8.  TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.

Authors:  M Labussière; A L Di Stefano; V Gleize; B Boisselier; M Giry; S Mangesius; A Bruno; R Paterra; Y Marie; A Rahimian; G Finocchiaro; R S Houlston; K Hoang-Xuan; A Idbaih; J-Y Delattre; K Mokhtari; M Sanson
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

Review 9.  Landscape of gene fusions in epithelial cancers: seq and ye shall find.

Authors:  Chandan Kumar-Sinha; Shanker Kalyana-Sundaram; Arul M Chinnaiyan
Journal:  Genome Med       Date:  2015-12-18       Impact factor: 11.117

10.  ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas.

Authors:  Hanseul Yang; Daniel Schramek; Rene C Adam; Brice E Keyes; Ping Wang; Deyou Zheng; Elaine Fuchs
Journal:  Elife       Date:  2015-11-21       Impact factor: 8.140

View more
  80 in total

1.  Salt bridge dynamics in protein/DNA recognition: a comparative analysis of Elk1 and ETV6.

Authors:  Tam D Vo; Amelia L Schneider; W David Wilson; Gregory M K Poon
Journal:  Phys Chem Chem Phys       Date:  2021-06-23       Impact factor: 3.676

2.  Loci-specific phase separation of FET fusion oncoproteins promotes gene transcription.

Authors:  Linyu Zuo; Guanwei Zhang; Matthew Massett; Jun Cheng; Zicong Guo; Liang Wang; Yifei Gao; Ru Li; Xu Huang; Pilong Li; Zhi Qi
Journal:  Nat Commun       Date:  2021-03-05       Impact factor: 14.919

3.  Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites.

Authors:  Bethany J Madison; Kathleen A Clark; Niraja Bhachech; Peter C Hollenhorst; Barbara J Graves; Simon L Currie
Journal:  J Biol Chem       Date:  2018-10-12       Impact factor: 5.157

4.  EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival.

Authors:  Zachary R Gallegos; Patrick Taus; Zane A Gibbs; Kathleen McGlynn; Nicholas C Gomez; Ian Davis; Angelique W Whitehurst
Journal:  Mol Cell Biol       Date:  2019-06-27       Impact factor: 4.272

5.  Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response.

Authors:  Christian F Aichmüller; Murat Iskar; David T W Jones; Andrey Korshunov; Bernhard Radlwimmer; Marcel Kool; Aurelie Ernst; Stefan M Pfister; Peter Lichter; Marc Zapatka
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

Review 6.  Importance of studying primitive neuroectodermal tumors and extraosseous Ewings sarcoma of the vagina and vulva.

Authors:  Adeline Tintila; Bogdan Doroftei; Delia Grab; Gabriela Simionescu; Emil Anton; Radu Maftei; Ciprian Ilea; Carmen Anton
Journal:  Oncol Lett       Date:  2021-01-04       Impact factor: 2.967

7.  Requisite endothelial reactivation and effective siRNA nanoparticle targeting of Etv2/Er71 in tumor angiogenesis.

Authors:  Ashraf Ul Kabir; Tae-Jin Lee; Hua Pan; Jeffrey C Berry; Karen Krchma; Jun Wu; Fang Liu; Hee-Kyoung Kang; Kristina Hinman; Lihua Yang; Samantha Hamilton; Qingyu Zhou; Deborah J Veis; Robert P Mecham; Samuel A Wickline; Mark J Miller; Kyunghee Choi
Journal:  JCI Insight       Date:  2018-04-19

8.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

9.  Dioxin-like and non-dioxin-like PCBs differentially regulate the hepatic proteome and modify diet-induced nonalcoholic fatty liver disease severity.

Authors:  Jian Jin; Banrida Wahlang; Hongxue Shi; Josiah E Hardesty; K Cameron Falkner; Kimberly Z Head; Sudhir Srivastava; Michael L Merchant; Shesh N Rai; Matthew C Cave; Russell A Prough
Journal:  Med Chem Res       Date:  2020-06-07       Impact factor: 1.965

10.  Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy.

Authors:  Yang Liu; Joseph M Eckenrode; Yinan Zhang; Jianjun Zhang; Reiya C Hayden; Annet Kyomuhangi; Larissa V Ponomareva; Zheng Cui; Jürgen Rohr; Oleg V Tsodikov; Steven G Van Lanen; Khaled A Shaaban; Markos Leggas; Jon S Thorson
Journal:  J Med Chem       Date:  2020-11-16       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.